ArticlePloS one2025
Machine learning-based prediction of metabolic dysfunction-associated steatotic liver disease using National Health and Nutrition Examination Survey (NHANES) data.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deep sequence learning with multi-task supervision for scalable population health monitoring.Frontiers in public health · 2026Article
- Interpretable Machine Learning Models for Early Detection of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Non-Invasive Routine Clinical and Laboratory Data.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWith the global increase in obesity rates and lifestyle changes, metabolic dysfunction-associated steatotic liver disease (MASLD) has become a prevalent chronic liver disorder, affecting approximately 25% of the global population. This disease can progress to cirrhosis and liver cancer, posing a significant threat to public health. To facilitate early diagnosis and intervention, this study aims to develop an efficient and reliable prediction model for MASLD using machine learning algorithm.
methodsThis study included 9,232 participants aged 20 years and older from the 2017-2020 National Health and Nutrition Examination Survey (NHANES). After excluding individuals with frequent alcohol consumption, hepatitis B/C infection, those lacking liver ultrasound examinations, and samples with missing data, a total of 2,460 subjects were ultimately included. The dataset was split into training and testing sets in an 80:20 ratio. Five machine learning algorithms-XGBoost, Random Forest (RF), and Logistic Regression (LR), among others-were utilized to build prediction models, while Recursive Feature Elimination (RFE) was employed to identify key predictive factors.
resultsComparison of the five algorithms revealed that the XGBoost algorithm performed the best. Twelve key features were selected through Recursive Feature Elimination (RFE), and the model achieved an AUC of 0.8740 on the testing set, demonstrating excellent predictive accuracy and discriminative ability. SHAP plot analysis of the model showed that waist circumference, BMI, and other factors played a pivotal role in the prediction of MASLD.
conclusionThe prediction model developed using the XGBoost algorithm and the 12 selected features demonstrates high efficiency and stability in assessing MASLD risk. This model offers innovative technical solutions and data-driven support for the clinical early identification of high-risk populations, with the potential to optimize and refine MASLD prevention and control strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.